Trial win, backlash mix
Lilly is slipping moderately alongside a soft S&P 500 while digesting mixed headlines, an in-house trial where its experimental combo beat Zepbound and doctor backlash over its Mounjaro direct-dispensing move, leaving the narrative conflicted rather than clearly negative.
Sources: https://pharma.economictimes.indiatimes.com/news/research-and-development/exp
Sources
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works